Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05337631 · ClinicalTrials.gov registry record
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
A clinical trial of Oropharynx Cancer and HNSCC, sponsored by University Hospital Freiburg.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 18
- Study locations
NCT05337631 is a study of Oropharynx Cancer and HNSCC that is actively recruiting participants, run by University Hospital Freiburg. The registered enrollment target is 1,500 participants, above the 74-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (1927% higher). The trial reports 18 study locations across 4 states.
The verdict
NCT05337631, a study of Oropharynx Cancer and HNSCC, is actively recruiting participants, sponsored by University Hospital Freiburg.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 18
- Study locations
Study Summary
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.
Conditions Studied
Study Locations (18)
Other
- Radiation Oncology Department, German Oncology Center - Limassol
- Brno University Hospital - Brno
- Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin - Berlin
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg - Erlangen
- Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main - Frankfurt
- University of Giessen - Giessen
- Martin-Luther-Universität Halle-Wittenberg - Halle
- Jena University Hospital - Jena
- Department of Radiation Oncology, University Hospital Schleswig-Holstein - Kiel
- Department of Radiation Oncology, University Medical Center Leipzig - Leipzig
- Department of Radiation Oncology, University Medical Center Mainz - Mainz
- Department of Radiation Oncology, University Hospital, LMU Munich - Munich
- Department of Radiation Oncology, University Hospital Würzburg - Würzburg
- Department of Radiation Oncology, University Hospital Zurich (USZ), University of Zurich (UZH) - Zurich
Ohio
- Department of Radiation Oncology, Case Western Reserve University - Cleveland
- Division of Radiation Oncology, The Ohio State University Wexner - Columbus
Maryland
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine - Baltimore
New York
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05337631
The ClinicalTrials.gov registry entry for NCT05337631 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 74-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (1927% higher). The listed sponsor is University Hospital Freiburg, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Oropharynx Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05337631 reports 18 study locations spanning 4 distinct geographic areas - top geographies include Other, Ohio, Maryland.
Frequently Asked Questions
What is clinical trial NCT05337631 about?
NCT05337631 is a clinical study titled "Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy". The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNS...
What is the current status of trial NCT05337631?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2021-06-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05337631 study?
This clinical trial studies the following conditions: Oropharynx Cancer, HNSCC, Oral Cavity Cancer, Larynx Cancer, Hypopharynx Cancer.
Who is sponsoring clinical trial NCT05337631?
This trial is sponsored by University Hospital Freiburg, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05337631 being conducted?
This trial has 18 study locations across Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
RECRUITING · Phase 2
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
-
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.